Table 2 Baseline circulatory pressure and volume status, kidney function and systemic inflammation
Characteristic | Tirzepatide (n = 364) | Placebo (n = 367) |
|---|---|---|
Baseline hemodynamics and volume status | ||
Systolic BP (mmHg) | 127.9 ± 13.1 | 128.2 ± 13.7 |
Diastolic BP (mmHg) | 75.7 ± 9.6 | 76.9 ± 10.0 |
Pulse pressure (mmHg) | 52.1 ± 12.7 | 51.2 ± 12.4 |
Estimated total BV (l) | 5.77 ± 0.96 | 5.74 ± 0.94 |
Estimated PV (l) | 3.34 ± 0.58 | 3.32 ± 0.57 |
Baseline kidney indices | ||
eGFR, ml min−1 1.73 m−2 | 55.5 ± 23.1 | 55.1 ± 21.7 |
Stage 3 or greater CKD, n (%) | 212 (58.2%) | 229 (62.4%) |
Cystatin C, median (IQR) (mg l−1) | 1.26 (1.04–1.63) | 1.29 (1.07–1.60) |
UACR, median (IQR), (g kg−1) | 17 (8–47) | 20 (8–65) |
Microalbuminuria (UACR 30–300), n (%) | 96 (26.5%) | 105 (28.9%) |
Macroalbuminuria (UACR >300), n (%) | 22 (6.1%) | 39 (10.7%) |
Systemic inflammation | ||
High-sensitivity CRP, median (IQR), mg l−1 | 3.1 (1.6–6.5) | 3.4 (1.4–6.4) |
Elevated CRP (>2 mg l−1), n (%) | 233 (66.6%) | 227 (65.6%) |
